The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 24, 2023

Filed:

Dec. 11, 2019
Applicant:

Kite Pharma, Inc., Santa Monica, CA (US);

Inventors:

Arianne Perez, Woodland Hills, CA (US);

Stuart A. Sievers, Van Nuys, CA (US);

Ruben Alvarez Rodriguez, Los Angeles, CA (US);

Jonathan Belk, Lebanon, NH (US);

Jed Wiltzius, Woodland Hills, CA (US);

Assignee:

Kite Pharma, Inc., Santa Monica, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C12N 5/10 (2006.01); C12N 15/63 (2006.01); A61K 35/17 (2015.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61P 35/00 (2018.01); C07K 16/2803 (2013.01); C07K 16/2887 (2013.01); C07K 16/2896 (2013.01); C12N 5/10 (2013.01); C12N 15/63 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01);
Abstract

Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20/anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.


Find Patent Forward Citations

Loading…